Skip to main content
. 2007 Jan 31;8(9):649–658. doi: 10.1111/j.1524-6175.2006.05689.x

Table III.

Time From Randomization to Onset of Angioedema in ALLHAT Participants*

Number (%) of Participants With Angioedema
Time from Randomization to Onset of Angioedema C A L D Total
<1 d 1 0 2 0 3
1–7 d 1 0 6 2 9
Total within first wk† 2 (25) 0 8 (22) 2 (40) 12 (23)
8–14 d 0 0 1 0 1
15–30 d 0 0 4 1 5
Total within first mo† 2 (25) 0 13 (35) 3 (60) 18 (34)
31–60 d 0 0 3 1 4
61–90 d 0 1 2 0 3
Total within first 3 mo† 2 (25) 1 (33) 18 (49) 4 (80) 25 (47)
91–182 d 0 1 3 0 4
6 mo–1 y 0 1 6 1 7
Total within first year† 2 (25) 3 (100) 27 (73) 5 (100) 36 (68)
1–2 y 0 0 3 0 4
>2–3y 1 0 3 0 4
>3–4y 3 0 2 0 5
>4–5y 0 0 1 0 1
>5–6y 1 0 1 0 2
>6 y 0 1 0 0 1
ALLHAT indicates Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial; C, chlorthalidone; A, amlodipine; L, lisinopril; and D, doxazosin. *For participants who experienced more than one episode of angioedema, only the first is considered. †Values are cumulative.